Neuropsychiatric manifestations of SLE (NPSLE) is associated with increased morbidity and mortality, intractable, complicating, and poor prognosis [1–3]. Although the severity of NPSLE correlates with poor prognosis, no established treatment protocol and resistance to general treatment in many cases are making this condition worse. Existing studies has shown expression of key B cell cytokines such as BAFF and IL-6 were increased in SLE [4,5]. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating SLE.
